Drug Information
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides fragilis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Dasatinib can be metabolized by Bacteroides fragilis. | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.482; p = 0.004). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Bifidobacterium ruminantium (log2FC = -0.533; p = 0.007). | |||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Dasatinib can be metabolized by Bifidobacterium ruminantium. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.38; p = 0.016). | |||
|
Studied Microbe: Clostridium bolteae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Description | Dasatinib can be metabolized by Clostridium bolteae. | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Clostridium sp. (log2FC = -0.485; p = 0.006). | |||
|
Studied Microbe: Enterocloster bolteae ATCC BAA-613
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Enterocloster bolteae ATCC BAA-613 (log2FC = -2.327; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus reuteri CF48-3A
Show/Hide Hierarchy
|
[7] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Dasatinib can be metabolized by Lactobacillus reuteri CF48-3A (log2FC = -0.961; p = 0.0). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [8], [9], [10] |
| Fyn tyrosine protein kinase (FYN) | Target Info | Inhibitor | [8], [9], [10] | |
| LCK tyrosine protein kinase (LCK) | Target Info | Inhibitor | [8], [9], [10] | |
| Proto-oncogene c-Src (SRC) | Target Info | Inhibitor | [8], [9], [10] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678). | |||
| REF 2 | 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. | |||
| REF 3 | Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007 Nov;29(11):2289-308. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 5 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. | |||
| REF 6 | Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci. 2020 Mar;13(2):238-259. | |||
| REF 7 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 8 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | |||
| REF 9 | In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. J Clin Pharmacol. 2008 Oct;48(10):1179-88. | |||
| REF 10 | Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.